Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 13/20 | 0.60 |
| ▸ | CDC42BPB | Q9Y5S2 | 13/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 12/20 | 0.60 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.60 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.54 |
| ▸ | CDK9 | P50750 | 7/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.54 |
| ▸ | CDK2 | P24941 | 6/20 | 0.54 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986128 | 0.90 | CCNT1 (0.65) | ROCK1CDC42BPBROCK2CDC42BPACCNT1 | |
| SCHEMBL2994705 | 0.88 | CCNT1 (0.68) | ROCK1CDC42BPBROCK2CDC42BPACCNT1 | |
| SCHEMBL2989444 | 0.81 | CCNT1 (0.67) | ROCK1CDC42BPBROCK2CDC42BPACCNT1 | |
| SCHEMBL24672184 | 0.81 | ROCK1 (0.88) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL29869691 | 0.81 | ROCK1 (0.88) | ROCK1CDC42BPBROCK2CDC42BPA | |
| SCHEMBL2991126 | 0.79 | CDK5 (0.67) | CCNT1CDK9CDK5CDK5R1CCNA2 | |
| SCHEMBL2994139 | 0.78 | CDK5 (0.71) | CCNT1CDK9CDK5CDK5R1CCNA2 | |
| SCHEMBL30093657 | 0.76 | ROCK1 (0.64) | ROCK1CDC42BPBROCK2CDC42BPACCNT1 | |
| SCHEMBL2990059 | 0.76 | CDK5 (0.71) | CCNT1CDK9CDK5CDK5R1CCNA2 | |
| SCHEMBL24672988 | 0.76 | ROCK2 (1.00) | ROCK1CDC42BPBROCK2CDC42BPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184790-A1 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184790-A1 | PYRROLO[2,3-B]PYRIDINE COMPOUNDS, AZAINDOLE COMPOUNDS USED FOR SYNTHESIZING SAID PYRROLO[2,3-B]PYRIDINE COMPOUNDS, METHODS FOR THE PRODUCTION THEREOF, AND USES THEREOF | BAD, PPOX, CASP3 | ROCK1 1379/4885CDC42BPB 1235/4885ROCK2 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.